16. Mylan $8.7B ▲10.3%
Global revenue: $12.0B (20th); up 7.0%
Top brands: EpiPen 2-Pak; Fentanyl (US sales revenue N/A)
Promotional spend: $111.4M (31st); 1.3% of rev.
R&D spend: $582M (19th); up 14.6%; 4.9% of rev.
Planned launches: Lidoderm generic (CNS); Copaxone generic (MS)
Patent expirations: N/A
Mylan could serve as a case study for the M&A frenzy currently sweeping the industry. For mid-size companies, it’s either buy or be bought. In April, just months after paying $5.3 billion for a share of Abbott Laboratories’ overseas generic business, Mylan made an offer for Ireland-based Perrigo. Rumors have circulated that the tender, which at press time was still pending, was either a defense against an imminent takeover bid from rival Teva or a way to drive up Mylan’s price if that takeover bid ever occurs. In any case, the Abbott deal allowed Mylan to shift its tax headquarters from Pittsburgh to the Netherlands, for a projected savings of 20%.
Click here to return to main story.
From the May 01, 2015 Issue of MM+M - Medical Marketing and Media
